Advisors Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Advisors Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-579	Closed	-$39K	–	1518
2022 Q2	$39K	Sell	579 -1,002	-63%	-$63.7K	﹤0.01%	1401
2022 Q1	$130K	Sell	1,581 -1,445	-48%	-$148K	﹤0.01%	1316
2021 Q4	$444K	Sell	3,026 -122	-4%	-$18.9K	0.01%	1038
2021 Q3	$557K	Sell	3,148 -11	-0.3%	-$1.77K	0.01%	972
2021 Q2	$510K	Buy	3,159 +1,220	+63%	+$196K	0.01%	995
2021 Q1	$332K	Buy	1,939 +1,269	+189%	+$251K	0.01%	1115
2020 Q4	$147K	Buy	+670	New	+$145K	﹤0.01%	1298

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Advisors Asset Management's MRTX Position: Q3 2022 in Review

Advisors Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2022, closing a stake of 579 shares — an estimated $39K sold.

Advisors Asset Management first reported a position in MRTX in Q4 2020 and held it in 7 quarters. The position peaked at $557K in Q3 2021. 243 funds tracked by Wall St. Rank hold MRTX as of Q3 2022.

Advisors Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Advisors Asset Management sold 579 Mirati Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $39K.
Advisors Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
Advisors Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $557K in Q3 2021.
243 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Advisors Asset Management's 13F filing for Q3 2022, filed 8 Nov 2022.